Nothing huge broke in the last day or two. The market barely moved: one of the biggest psychedelic companies, Compass, slipped a little (down about 2%), while a smaller rival, MindMed, ticked up almost 2%. No new deals, no surprise government announcements. The freshest thread running through today's data is about people, not products — specifically, the growing political noise around two things: giving ibogaine (a plant medicine being tested for trauma and addiction) to military veterans, and the new leadership at the FDA, the agency that decides which drugs Americans can legally use.
Here is what the swarm of forecasts keeps landing on. Even with the president applauding and a Joe Rogan-connected figure now helping steer FDA policy, the people who make the swarm's best guesses put a 68% to 70% chance on this: none of that will speed up the actual reviews or loosen the actual rules this year. Ibogaine stays in the government's most restricted drug category — the "you can only touch it for approved research" box. Any veteran program moves only inside that narrow research lane. And the long-delayed decision on MDMA for post-traumatic stress (the mental wound many veterans carry) will follow its normal timetable, not a rushed one.
The deeper current is this: excitement and law are two different rivers. The excitement river is loud and fast right now. The law river is quiet and slow, and it does not change course because someone famous shouted at it. That can feel frustrating. But look closer and you see something hopeful. The slowness is actually protection. Ibogaine can strain the heart — that risk is real, and rushing past it would get someone hurt and set the whole field back years. The most positive path available is not the fastest one. It is the one where the science is done so cleanly that when approval finally comes, no one can knock it down. The forecasts also expect real movement at the state level and in Congress this fall — just aimed carefully at veterans and research, the doors most likely to open first and hold.
For the veteran sitting at a kitchen table tonight, unable to sleep, out of options after everything else failed — this is the part that matters. The applause on television can feel like a promise. And when the rules don't instantly change, it can feel like betrayal. But the honest, hopeful truth is that a solid research lane is being widened right now, and it is the lane most likely to reach you in a form that lasts — not a headline that fades, but a treatment a doctor can actually give you, safely, without it being yanked away later. The wait is real. So is the ground being laid beneath it.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
This is not prediction. This is recognition.
70%
Ibogaine research stays tightly restricted for veterans this year
The DEA (the US agency that controls which drugs can be studied or used) is keeping ibogaine — a powerful plant-based substance showing promise for addiction and PTSD — locked under its strictest research rules. Any study involving veterans must go through a lengthy, formal approval process called a Schedule I research registration. There's no special fast-track or emergency-access pathway being created in 2026, even though some politicians have cheered the idea.
→ Political enthusiasm for ibogaine hasn't changed the actual rules, so legal US access remains years away.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
DEA maintains restrictive research-exemption posture on ibogaine; any veteran pilot proceeds only under Schedule I research registration with no expanded-access carve-out this year.. Presidential applause doesn't change diversion-control law. Ibogaine's cardiac risk profile makes any loosening a liability nightmare I'll be asked to justify to communities.
68%
Political pressure won't speed up the US government's MDMA therapy decision
The FDA (the US drug regulator) rejected a company called Lykos Therapeutics' application to approve MDMA-assisted therapy in 2024 and asked for more data. A new FDA official with ties to podcaster Joe Rogan has been appointed, raising hopes among some that the review might speed up. This prediction says that won't happen — the review will follow its normal, legally scheduled timeline, and no fast-tracked decision will be announced in the next few months.
→ A politically connected FDA appointee doesn't mean MDMA therapy gets approved faster — the standard review process is still running the clock.
Resolves: 2026-11-20 · USA
REGULATORY
the precise call ▾
The Rogan-architect FDA appointee will not shorten the Lykos/MDMA review timeline; any decision follows standard PDUFA cadence with no expedited action announced this quarter.. Political appointment optics don't override division-level review rigor. Fast-tracking on ideology invites litigation and erodes the standard patients depend on.
66%
No big psychedelic company buyouts or deals expected in the next two months
In the business world, a merger or licensing deal worth more than $50 million is a sign that big money is taking a sector seriously. This prediction says no such deal will happen in psychedelic biotech before mid-October 2026. It also says that a company called MMED (Mind Medicine) is outperforming a competitor called CMPS (Compass Pathways) in stock performance, and that gap will likely continue without a major scientific milestone from Compass.
→ Big money is sitting on the sidelines in psychedelic biotech until there's hard clinical evidence, so don't expect major deals before October 2026.
Resolves: 2026-10-20 · USA
MARKETS
the precise call ▾
No psychedelic biotech M&A or licensing deal >$50M is announced within 60 days; CMPS continues underperforming MMED absent a Phase 3 readout catalyst.. Institutional capital waits on de-risked assets. Ibogaine political noise doesn't move deal committees. MMED's relative strength signals where smart money positions.
63%
Ibogaine buzz won't trigger a major psychedelic industry deal by October
Even though ibogaine is getting political attention — especially around helping veterans — that buzz isn't expected to trigger a large buyout or licensing deal in the psychedelic biotech space before mid-October 2026. Meanwhile, MMED continues to trade better than CMPS in the stock market, suggesting investors see MMED as the stronger near-term bet.
→ Ibogaine is getting political attention, but big investors aren't writing checks yet — no major deal is expected before mid-October 2026.
Resolves: 2026-11-19 · USA
MARKETS
the precise call ▾
No psychedelic biotech M&A/licensing deal >$50M within 60 days despite ibogaine momentum; MMED holds relative strength over CMPS.. Consensus of 1 agents: investor. 1 dissenting.
65%
Rogan-linked FDA official draws ethics scrutiny but doesn't speed up MDMA review
The newly appointed FDA official connected to Joe Rogan is attracting news coverage questioning whether there's a conflict of interest — Rogan has publicly supported psychedelic therapies and the people behind them. Despite the noise, this prediction says the official won't actually change how fast the MDMA therapy review moves. The controversy creates headlines, but not policy change.
→ The controversy around the Rogan-linked FDA official is a distraction — it's generating coverage, not accelerating drug approvals.
Resolves: 2026-10-20 · USA
CULTURE
the precise call ▾
The Rogan-linked FDA appointee generates ethics/conflict coverage without shortening the Lykos/MDMA review timeline.. Consensus of 2 agents: fda_reviewer, journalist. 1 dissenting.